文献速递甲状腺与浅表US

靶向超声造影剂联合BRAFV600E突变诊断高危甲状腺乳头状癌的实验研究

Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation: An Experimental Study.
PubMed 文献 · J Ultrasound Med · 2022-03-01

本研究制备携带BRAFV600E抗体的靶向脂质纳米泡,在过表达突变BRAFV600E的甲状腺乳头状癌细胞(B-CPAP)及裸鼠移植瘤模型中评估其靶向结合与超声增强效果。靶向纳米泡形态均匀、稳定性好,在过表达BRAFV600E的肿瘤中超声增强和峰值强度均优于非靶向纳米泡(P < .001)。作者认为其有望作为诊断高危甲状腺乳头状癌的潜在靶向超声造影剂。

要点

  • 携带BRAFV600E抗体的靶向脂质纳米泡在过表达突变BRAFV600E的PTC肿瘤中超声增强效果优于非靶向纳米泡。
  • 靶向纳米泡在过表达突变BRAFV600E的PTC细胞中表现出良好的靶向诊断能力。
  • 靶向纳米泡时间-强度曲线峰值强度较非靶向纳米泡增高(P < .001)。

核心结论

  • 携带BRAFV600E抗体的靶向脂质纳米泡可被视为诊断高危甲状腺乳头状癌的潜在靶向超声造影剂。

研究设计与样本

  • 实验研究:采用薄膜水化-超声法和亲和素-生物素结合法制备携带BRAFV600E抗体的靶向脂质纳米泡,在过表达突变BRAFV600E的PTC细胞(B-CPAP)及裸鼠PTC肿瘤模型中评估靶向结合能力与超声增强效果,对照为非靶向脂质纳米泡。

关键影像表现/征象

  • 靶向脂质纳米泡呈均匀圆形形态,稳定性好,粒径为纳米级。
  • BRAFV600E单克隆抗体结合于脂质纳米泡表面。
  • 在过表达突变BRAFV600E的PTC肿瘤中,靶向纳米泡的超声增强效果和时间-强度曲线峰值强度均优于非靶向脂质纳米泡(P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: High-risk papillary thyroid carcinoma (PTC) patients with BRAF mutation have lymph node and distant metastases and poor prognosis. Therefore, this study aims to develop a targeted ultrasound contrast agent for the BRAFV600E mutation to screen high-risk PTC at early stage.

METHODS: The targeted lipid nanobubbles carrying BRAFV600E antibody were prepared using thin film hydration-sonication and avidin-biotin binding methods. The physicochemical properties and stability of the targeted nanobubbles were detected by transmission electron microscopy, atomic force microscopy, and confocal laser scanning microscopy. The target binding abilities of the targeted nanobubbles in the PTC cells (B-CPAP) overexpressed mutant BRAFV600E were evaluated by immunofluorescence staining, quantitative real-time polymerase chain reaction, western blot, and fluorescence microscopy. After PTC tumor models overexpressed mutant BRAFV600E were established, the enhanced images of targeted lipid nanobubbles and untargeted lipid nanobubbles on PTC tumors in nude mice were observed using contrast-enhanced ultrasound imaging.

RESULTS: The targeted lipid nanobubbles revealed uniform, round morphology, and good stability with a nanoscale size. Besides, BRAFV600E monoclonal antibody was observed to be combined on the surface of lipid nanobubbles. Furthermore, the targeted nanobubbles had a good targeting diagnosis ability in PTC cells with BRAFV600E overexpression. Moreover, the targeted nanobubbles had better ultrasound enhancement and peak intensity of the time-intensity curve (P < .001) in PTC tumors with BRAFV600E overexpression as compared to the untargeted lipid nanobubbles.

CONCLUSION: The targeted lipid nanobubbles carrying BRAFV600E antibody could be regarded as a potential targeted ultrasound contrast agent for the diagnosis of high-risk PTC.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Xie, Yan, Li, et al. Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation: An Experimental Study. J Ultrasound Med. 2022. PMID: 35229905. doi:10.1002/jum.15967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。